Express Mail No.: EL 451 599 156 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux, *et al.*

Filed: December 17, 1999

For: APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

Serial No.: 09/465,718

Group Art Unit: 1631

Examiner: Borin

Attorney Docket No.: 9196-018-999

Confirmation No.: 9219

FEE TRANSMITTAL SHEET

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be $0.

The claim amendment fee has been estimated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY			OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDIT. FEE	OR	RATE	ADDIT. FEE
TOTAL	29	MINUS	62	=	0	× 9	$ 0.00		× 18	$
INDEP.	01	MINUS	03	=	0	× 42	$ 0.00		× 84	$
☐ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						140	$		280	$
						TOTAL	$ 0.00	OR	TOTAL	$

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Date December 18, 2002

42,983

Rahul Pathak
for Laura A. Coruzzi

Reg. No.
(Reg. No. 30,742)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(650) 493-4935

Enclosure

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dasseux, *et al.*

Serial No.: 09/465,718

Filed: December 17, 1999

Group Art Unit: 1631

For: APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT DYSLIPIDEMIC DISORDERS

Examiner: Borin

Attorney Docket No.: 9196-018-999

Confirmation No.: 9219

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.114

Commissioner for Patents
Washington, D.C. 20231

Sir:

Reconsideration of the claims in light of the amendments and remarks that follow is kindly solicited. Enclosed herewith are Exhibits A (Claim Amendments: Version with Markings to Show Changes Made) and B (Claim Amendments: Pending Claims After Entry of the Instant Amendment), Fee Transmittal Sheet, Terminal Disclaimer, Terminal Disclaimer Fee Transmittal and Request for Continued Examination.

AMENDMENT

TO THE CLAIMS

Please cancel Claims 20-35, 43-55, 64-66 and 80-81 without prejudice.

Please amend Claims 1, 56-63, 67-75, 79, 82 and 83 to read as follows:

---

1. (Twice amended) An ApoA-I agonist compound comprising:

(i) a 15 to 26- residue peptide or peptide analogue according to formula (I) which forms an amphipathic α-helix in the presence of lipids and exhibits at least about 38% LCAT activation activity as compared with human ApoA-I wherein one or two helical turns are